Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RenovoRx (RNXT) Cash & Equivalents (2023 - 2025)

RenovoRx's Cash & Equivalents history spans 3 years, with the latest figure at $7.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 1.82% to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 1.82% decrease, with the full-year FY2025 number at $7.0 million, down 1.82% from a year prior.
  • Cash & Equivalents hit $7.0 million in Q4 2025 for RenovoRx, down from $10.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RNXT hit a ceiling of $14.6 million in Q1 2025 and a floor of $1.2 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $8.7 million across 3 years, with a median of $9.6 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: soared 509.89% in 2024 and later fell 1.82% in 2025.
  • Tracing RNXT's Cash & Equivalents over 3 years: stood at $1.2 million in 2023, then soared by 509.89% to $7.2 million in 2024, then decreased by 1.82% to $7.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for RNXT at $7.0 million in Q4 2025, $10.0 million in Q3 2025, and $12.3 million in Q2 2025.